<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102218</url>
  </required_header>
  <id_info>
    <org_study_id>2010-01</org_study_id>
    <nct_id>NCT01102218</nct_id>
  </id_info>
  <brief_title>A Safety Study of Pentoxifylline for the Treatment of Anemia</brief_title>
  <official_title>A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care North America</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative
      stress, which in turn contribute to anemia and cardiovascular disease.

      Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown
      promise in improving the treatment of patients with anemia. This study will examine the use
      of pentoxifylline for the treatment of anemia in chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of the anemia of renal failure has been revolutionized by the use of erythropoietin
      and other ESAs (erythropoiesis-stimulating agent). Concerns with ESA use include a
      substantial number of End Stage Renal Disease (ESRD) patients with ESA-resistant anemia, and
      a growing body of evidence of potential negative effects of high doses of ESA use, including
      increased mortality and increased rate of tumor growth in cancer patients.

      There are only a couple of small studies in the literature examining the effects of
      pentoxifylline on anemia in patients with renal failure. The results are limited by the very
      small number of patients. There is clearly a need for a larger, prospective, clinical trial
      of pentoxifylline in ESRD patients, not limited to those with ESA-resistant anemia. This
      would be the first prospective, randomized clinical trial of this size to study
      pentoxifylline for the treatment of anemia in chronic kidney disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of statistical difference between both arms of the trial.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Erythropoietin Dose</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Erythropoietin dose is amount needed to maintain a hemoglobin between 11 and 12 mg/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine the EPO Resistance Index (Erythropoietin Dose/kg/Week/Hgb) or ERI Over Time</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observe Changes in Markers of Inflammation Including But Not Limited to TNF-α and IL-6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>erythropoietin plus pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>erythropoietin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>erythropoietin plus pentoxifylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>erythropoietin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400 mg qd po for 6 months</description>
    <arm_group_label>erythropoietin plus pentoxifylline</arm_group_label>
    <other_name>brand name is Trental</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged ≥18 years;

          -  Able to comply with the study procedures and medication;

          -  Written informed consent given;

          -  On a stable in-center hemodialysis regimen (at least 3 times per week) for ≥ 12 weeks
             prior to screening;

          -  Subject must have been on a stable (&lt; 25% change) erythropoietin dose with an average
             of ≥ 15,000 and &lt;55,000 units/week of treatment for ≥ 14 days prior to screening
             visit;

          -  Two hemoglobin measurements must meet the following criteria: (1) Taken ≥ 2 weeks
             apart; (2) Between 10 and 12 g/dL, inclusive; (3) Within 1 g/dL of each other; and (4)
             Occurred within 30 days prior to screening visit;

          -  If subject is a female and of childbearing potential (pre-menopausal and not
             surgically sterile), subject is willing to use an effective contraceptive method
             throughout study, which includes abstinence, barrier methods, hormones, or IUDs;

          -  Life expectancy of 12 months or greater;

          -  Most recent single pool Kt/V ≥1.2, taken within 45 days prior to screening visit;

          -  Stable nutrition status with all albumin levels ≥ 3.0 g/dL within the 30 days prior to
             screening visit.

        Exclusion Criteria:

          -  Participation in any clinical trial using an investigational product or device during
             the 30 days preceding the Screening Visit;

          -  Currently undergoing nocturnal hemodialysis;

          -  A significant history of alcohol, drug or solvent abuse in the opinion of the
             investigator;

          -  Serum iPTH &gt; 800 pg/mL within 90 days prior to screening visit;

          -  Dysrhythmia or severe cardiac disease: CHF Class III-IV; unstable cardiovascular
             diagnosis (for example MI, CABG, PTCA, CVA, and TIA) within 90 days prior to screening
             visit;

          -  Significant concurrent liver disorder [Aspartate transaminase (AST) or alanine
             transaminase (ALT) values &gt; 3 times upper limit of normal (ULN) within 30 days prior
             to screening];

          -  Platelet count &lt; 130x109 within 30 days prior to screening visit or on the day of the
             screening visit;

          -  Known hypersensitivity to, or intolerance of, Pentoxifylline or other methylxanthines,
             such as caffeine, theophylline or theobromine;

          -  Currently taking pentoxifylline, warfarin, theophylline, aminophylline, dyphylline, or
             oxtriphylline;

          -  Absolute or functional iron deficiency [transferrin saturation (TSAT) &lt;20%] within 45
             days prior to screening;

          -  Recent or severe hemorrhage per PI discretion;

          -  Significant bleeding episode or prolonged bleeding from dialysis access per PI
             judgment within the 3 months prior to screening;

          -  Melatonin treatment, androgen therapy or blood transfusion within 30 days prior to
             screening;

          -  Vitamin C therapy at dose greater than 100 mg/day or at a dose which has changed
             within the last 3 months;

          -  Current active cancer (excluding basal cell carcinoma of the skin);

          -  Poorly controlled hypertension per PI judgment within 4 weeks prior to screening;

          -  Known HIV positive status;

          -  Significant GI disorders where absorption of an oral medication might, in the opinion
             of the Investigator, be impaired;

          -  Anticipated live donor kidney transplant or any other planned major surgery over the
             study duration;

          -  History of poor adherence to hemodialysis or medical regimen;

          -  Any active clinically significant infection or evidence of an underlying infection;

          -  Currently on immunosuppressive drug regimen other than a stable, low dose of steroids,
             per PI judgment;

          -  Any disease or condition, physical or psychological that, in the opinion of the
             investigator, would compromise the safety of the subject or the likelihood of
             achieving reliable results or increase the likelihood of the subject being withdrawn.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond M. Hakim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fresenius Medical Care North America</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Brookhaven</city>
        <state>Mississippi</state>
        <zip>39601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>St. Ann</city>
        <state>Missouri</state>
        <zip>63074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <results_first_submitted>January 18, 2012</results_first_submitted>
  <results_first_submitted_qc>February 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2012</results_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia, ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at Fresenius Medical Care North America Dialysis clinics between August 2010 and October 2011.</recruitment_details>
      <pre_assignment_details>There was no wash out or run in period for this trial.68 subjects signed informed consent, and 48 subjects were randomized.13 of the 20 screen failures were due to exclusionary lab values, 3 due to excluded medications, and 3 were due to other exclusion criteria, 1 due to unrelated SAE. Zero patients withdrew consent prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Erythropoietin Plus Pentoxifylline</title>
          <description>Standard of care prescribed erythropoietin dose plus 400mg oral pentoxifylline once a day.</description>
        </group>
        <group group_id="P2">
          <title>Erythropoietin Alone</title>
          <description>Standard of care prescribed erythropoietin dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erythropoietin Plus Pentoxifylline</title>
          <description>Standard of care prescribed erythropoietin dose plus 400mg oral pentoxifylline once a day.</description>
        </group>
        <group group_id="B2">
          <title>Erythropoietin Alone</title>
          <description>Standard of care prescribed erythropoietin dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="12"/>
                    <measurement group_id="B2" value="57" spread="14"/>
                    <measurement group_id="B3" value="56" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Erythropoietin Dose</title>
        <description>Erythropoietin dose is amount needed to maintain a hemoglobin between 11 and 12 mg/dL.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>The number of patients for analysis was based on those patient who had completed 6 months of treatment. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythropoietin Plus Pentoxifylline</title>
            <description>Standard of care prescribed erythropoietin dose plus 400mg oral pentoxifylline once a day.</description>
          </group>
          <group group_id="O2">
            <title>Erythropoietin Alone</title>
            <description>Standard of care prescribed erythropoietin dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Erythropoietin Dose</title>
          <description>Erythropoietin dose is amount needed to maintain a hemoglobin between 11 and 12 mg/dL.</description>
          <population>The number of patients for analysis was based on those patient who had completed 6 months of treatment. The analysis was per protocol.</population>
          <units>Units EPO</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8700" spread="12586"/>
                    <measurement group_id="O2" value="-2988" spread="10232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine the EPO Resistance Index (Erythropoietin Dose/kg/Week/Hgb) or ERI Over Time</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observe Changes in Markers of Inflammation Including But Not Limited to TNF-α and IL-6</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erythropoietin Plus Pentoxifylline</title>
          <description>Standard of care prescribed erythropoietin dose plus 400mg oral pentoxifylline once a day.</description>
        </group>
        <group group_id="E2">
          <title>Erythropoietin Alone</title>
          <description>Standard of care prescribed erythropoietin dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Access related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Access-related</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After Sponsor’s (S) publication (pub) of multi-center pub,Institution (I) and/or Principal Investigator (PI) may publish data/results from Study based solely upon Study conducted by I/PI,provided that I/PI submits pub to S for review/comment &gt; 60 days before date of proposed pub.S may review in advance contents of pub.If pub is not submitted within 12 months after termination of Study at all sites,or if S confirms there will be no pub,the I/PI may publish Study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Release of new FDA guidelines re target Hgb values impacted EPO dosing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christina Kahn, Senior Manager of Clinical Trials</name_or_title>
      <organization>Fresenius Medical Care North America</organization>
      <phone>615-345-5542</phone>
      <email>christina.meng@fmc-na.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

